Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;70(2):191-198.
doi: 10.1053/j.ajkd.2016.11.018. Epub 2017 Feb 10.

Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD

Sankar D Navaneethan  1 , Jesse D Schold  2 , Stacey E Jolly  3 , Susana Arrigain  4 , Wolfgang C Winkelmayer  5 , Joseph V Nally Jr  4
Affiliations

Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD

Sankar D Navaneethan et al. Am J Kidney Dis. 2017 Aug.

Abstract

Background: Diabetes is the leading cause of end-stage renal disease (ESRD) and a significant contributor to mortality in the general population. We examined the associations of hemoglobin A1c (HbA1c) levels with ESRD and death in a population with diabetes and chronic kidney disease (CKD).

Study design: Cohort study.

Setting & participants: 6,165 patients with diabetes (treated with oral hypoglycemic agents and/or insulin) and CKD stages 1 to 5 at a large health care system.

Predictor: HbA1c level (examined as a categorical and continuous measure).

Outcomes: All-cause and cause-specific mortality ascertained from the Ohio Department of Health mortality files and ESRD ascertained from the US Renal Data System.

Results: During a median 2.3 years of follow-up, 957 patients died (887 pre-ESRD deaths) and 205 patients reached ESRD. In a Cox proportional hazards model, after multivariable adjustment including for kidney function, HbA1c level < 6% was associated with higher risk for death when compared with HbA1c levels of 6% to 6.9% (HR, 1.23; 95% CI, 1.01-1.50). Similarly, HbA1c level ≥ 9% was associated with higher risk for all-cause death (HR, 1.34; 95% CI, 1.06-1.69). In competing-risk models, baseline HbA1c level was not associated with ESRD. For cause-specific mortality, diabetes accounted for >12% of deaths overall and >19% of deaths among those with HbA1c levels > 9%.

Limitations: Small proportion of participants with advanced kidney disease; single-center population.

Conclusions: In this cohort of patients with CKD with diabetes, HbA1c levels < 6% and ≥9% were associated with higher risk for death. HbA1c levels were not associated with ESRD in this specific CKD population. Diabetes-related deaths increased with higher HbA1c levels.

Keywords: Glycated hemoglobin; HbA(1c); chronic kidney disease (CKD); death and kidney disease; diabetes control; diabetes mellitus; diabetic nephropathy; end stage renal disease (ESRD); incident ESRD; mortality.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure

Dr Navaneethan has served as consultant for Bayer and Boeringher-Ingelheim. The other authors declare that they have no relevant financial interests.

Figures

Figure 1
Figure 1
Cumulative incidence curves for end-stage renal disease (ESRD) and death among patients with chronic kidney disease across hemoglobin A1c categories using competing risks.
Figure 2
Figure 2
Associations of hemoglobin A1c (HbA1c) with all-cause mortality (baseline HbA1c considered as continuous measure with splines at the 10th, 50th, and 90th percentile: 5.8, 6.9, and 9.1 respectively; main effect P = 0.07, nonlinear P = 0.04).
See this image and copyright information in PMC

References

    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. - PubMed
    1. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–814. - PubMed
    1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539. - PMC - PubMed
    1. USRDS. Incidence, prevalence, patient characteristics, and treatment modalities. 2016;2016(08/04)
    1. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. - PubMed

Substances